Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/the-new-england-journal-of-medicine/systemic-therapy-for-metastatic-renal-cell-carcinoma-0amZWVQd6D
References (90)
-
B. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, T. Hutson, M. Michaelson, V. Gorbunova, M. Gore, I. Rusakov, S. Négrier, Y. Ou, D. Castellano, Ho Lim, H. Uemura, J. Tarazi, D. Cella, Connie Chen, B. Rosbrook, S. Kim, R. Motzer (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 378
-
A. Lipton, A. Colombo-Berra, R. Bukowski, L. Rosen, M. Zheng, G. Urbanowitz (2004)
Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic AcidClinical Cancer Research, 10
-
R. Motzer, C. Barrios, Tae Kim, S. Falcón, T. Cosgriff, W. Harker, V. Srimuninnimit, K. Pittman, R. Sabbatini, S. Rha, T. Flaig, R. Page, S. Bavbek, J. Beck, P. Patel, F. Cheung, S. Yadav, E. Schiff, Xufang Wang, J. Niolat, D. Sellami, O. Anak, J. Knox (2014)
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 25
-
D. Kwiatkowski, T. Choueiri, A. Fay, A. Fay, B. Rini, A. Thorner, G. Velasco, M. Tyburczy, L. Hamieh, L. Albiges, N. Agarwal, T. Ho, Jiaxi Song, Jean-Christophe Pignon, P. Barrios, M. Michaelson, E. Allen, K. Krajewski, C. Porta, S. Pal, J. Bellmunt, D. McDermott, D. Heng, K. Gray, S. Signoretti (2016)
Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaClinical Cancer Research, 22
-
G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Starosławska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovačević, V. Lesovoy, I. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore, R. Motzer (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.The New England journal of medicine, 356 22
-
T. Choueiri, T. Choueiri, A. Fay, K. Gray, M. Callea, T. Ho, L. Albiges, J. Bellmunt, J. Bellmunt, Jiaxi Song, I. Carvo, M. Lampron, M. Stanton, F. Hodi, D. McDermott, D. McDermott, M. Atkins, G. Freeman, M. Hirsch, M. Hirsch, S. Signoretti, S. Signoretti (2014)
PD-L1 expression in nonclear-cell renal cell carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology, 25 11
-
B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard, M. Staehler, S. Négrier, C. Chevreau, A. Desai, F. Rolland, T. Demkow, Thomas Hutson, M. Gore, S. Anderson, G. Hofilena, M. Shan, C. Peña, C. Lathia, R. Bukowski (2009)
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 20
-
R. Motzer, Thomas Hutson, M. Ren, C. Dutcus, J. Larkin (2016)
Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.The Lancet. Oncology, 17 1
-
R. Motzer, Thomas Hutson, D. Cella, J. Reeves, R. Hawkins, Jun Guo, P. Nathan, M. Staehler, P. Souza, J. Merchan, E. Boleti, K. Fife, Jie Jin, Robert Jones, H. Uemura, U. Giorgi, U. Harmenberg, Jinwan Wang, C. Sternberg, K. Deen, L. McCann, M. Hackshaw, R. Crescenzo, L. Pandite, T. Choueiri (2013)
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.The New England journal of medicine, 369 8
-
R. McKay, Xun Lin, J. Perkins, D. Heng, R. Simantov, T. Choueiri (2014)
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.European urology, 66 3
-
N. Tannir, E. Jonasch, L. Albiges, E. Altinmakas, C. Ng, S. Matin, Xuemei Wang, W. Qiao, Z. Lim, P. Tamboli, P. Rao, K. Sircar, J. Karam, D. McDermott, C. Wood, T. Choueiri (2016)
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.European urology, 69 5
-
E. Diamond, A. Molina, Marisa Carbonaro, N. Akhtar, P. Giannakakou, S. Tagawa, D. Nanus (2015)
Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.Critical reviews in oncology/hematology, 96 3
-
W. Linehan, P. Spellman, C. Ricketts, C. Creighton, S. Fei, Caleb Davis, D. Wheeler, Bradley Murray, L. Schmidt, C. Vocke, Myron Peto, A. Mamun, E. Shinbrot, A. Sethi, S. Brooks, W. Rathmell, Angela Brooks, K. Hoadley, A. Robertson, Denise Brooks, R. Bowlby, S. Sadeghi, Hui Shen, D. Weisenberger, M. Bootwalla, S. Baylin, P. Laird, A. Cherniack, G. Saksena, S. Haake, Jun Li, Han Liang, Yiling Lu, G. Mills, R. Akbani, Mark Leiserson, Benjamin Raphael, Pavana Anur, D. Bottaro, L. Albiges, N. Barnabas, T. Choueiri, B. Czerniak, A. Godwin, A. Hakimi, T. Ho, J. Hsieh, M. Ittmann, William Kim, B. Krishnan, M. Merino, Kenna Shaw, V. Reuter, E. Reznik, C. Shelley, B. Shuch, S. Signoretti, R. Srinivasan, P. Tamboli, G. Thomas, S. Tickoo, K. Burnett, D. Crain, J. Gardner, Kevin Lau, D. Mallery, S. Morris, J. Paulauskis, R. Penny, C. Shelton, W. Shelton, M. Sherman, E. Thompson, P. Yena, Melissa Avedon, Jay Bowen, J. Gastier-Foster, M. Gerken, K. Leraas, T. Lichtenberg, N. Ramirez, T. Santos, L. Wise, E. Zmuda, John Demchok, Ina Felau, C. Hutter, Margi Sheth, H. Sofia, R. Tarnuzzer, Zhining Wang, Liming Yang, J. Zenklusen, J. Zhang, Brenda Ayala, J. Baboud, Sudha Chudamani, Jia Liu, Laxmi Lolla, R. Naresh, T. Pihl, Qiang Sun, Yunhu Wan, Ye Wu, Adrian Ally, M. Balasundaram, S. Balu, R. Beroukhim, T. Bodenheimer, C. Buhay, Y. Butterfield, R. Carlsen, S. Carter, H. Chao, E. Chuah, A. Clarke, K. Covington, M. Dahdouli, N. Dewal, Noreen Dhalla, H. Doddapaneni, J. Drummond, S. Gabriel, R. Gibbs, R. Guin, Walker Hale, A. Hawes, D. Hayes, R. Holt, A. Hoyle, S. Jefferys, Steven Jones, Corbin Jones, D. Kalra, C. Kovar, L. Lewis, Jie Li, Yussanne Ma, M. Marra, Michael Mayo, S. Meng, M. Meyerson, P. Mieczkowski, Richard Moore, Donna Morton, Lisle Mose, A. Mungall, D. Muzny, J. Parker, C. Perou, J. Roach, J. Schein, S. Schumacher, Yan Shi, J. Simons, Payal Sipahimalani, Tara Skelly, Matthew Soloway, C. Sougnez, Angela Tam, Donghui Tan, N. Thiessen, Umadevi Veluvolu, Min Wang, M. Wilkerson, Tina Wong, Junyuan Wu, Liu Xi, Jane Zhou, Jason Bedford, Fengju Chen, Yao Fu, M. Gerstein, D. Haussler, K. Kasaian, Phillip Lai, Shiyun Ling, Amie Radenbaugh, D. Berg, J. Weinstein, Jingchun Zhu, Monique Albert, I. Alexopoulou, Jeremiah Andersen, J. Auman, J. Bartlett, S. Bastacky, Julie Bergsten, M. Blute, L. Boice, R. Bollag, J. Boyd, E. Castle, Ying-bei Chen, J. Cheville, Erin Curley, B. Davies, April DeVolk, R. Dhir, Laura Dike, J. Eckman, J. Engel, Jodi Harr, R. Hrebinko, Meijuan Huang, L. Huelsenbeck-Dill, M. Iacocca, B. Jacobs, M. Lobis, J. Maranchie, S. McMeekin, J. Myers, J. Nelson, J. Parfitt, A. Parwani, N. Petrelli, B. Rabeno, Somak Roy, A. Salner, J. Slaton, M. Stanton, R. Thompson, L. Thorne, Kelinda Tucker, P. Weinberger, C. Winemiller, L. Zach, R. Zuna (2016)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.The New England journal of medicine, 374 2
-
E. Jonasch, L. Lal, B. Atkinson, S. Byfield, L. Miller, L. Pagliaro, C. Feng, N. Tannir (2011)
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centreBJU International, 107
-
G. Malouf, F. Monzon, J. Couturier, V. Molinie, B. Escudier, P. Camparo, X. Su, Hui Yao, P. Tamboli, D. Lopez-Terrada, M. Picken, M. Garcia, A. Multani, S. Pathak, C. Wood, N. Tannir (2013)
Genomic Heterogeneity of Translocation Renal Cell CarcinomaClinical Cancer Research, 19
-
A. Napoli, S. Signoretti (2009)
Tissue biomarkers in renal cell carcinoma: Issues and solutionsCancer, 115
-
J. Kavolius, D. Mastorakos, C. Pavlovich, P. Russo, M. Burt, M. Brady (1998)
Resection of metastatic renal cell carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 16 6
-
D. Heng, W. Xie, M. Regan, L. Harshman, G. Bjarnason, U. Vaishampayan, M. Mackenzie, L. Wood, F. Donskov, M. Tan, S. Rha, N. Agarwal, C. Kollmannsberger, B. Rini, T. Choueiri (2013)
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.The Lancet. Oncology, 14 2
-
C. Allard, F. Gelpi‐Hammerschmidt, L. Harshman, T. Choueiri, I. Faiena, Parth Modi, B. Chung, I. Tinay, E. Singer, Steven Chang (2015)
Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.Urologic oncology, 33 11
-
I. Gill, M. Aron, D. Gervais, M. Jewett (2010)
Clinical practice. Small renal mass.The New England journal of medicine, 362 7
-
J. Rosenblatt, D. McDermott (2011)
Immunotherapy for renal cell carcinoma.Hematology/oncology clinics of North America, 25 4
-
B. Rini, J. Bellmunt, J. Clancy, Kongming Wang, A. Niethammer, S. Hariharan, B. Escudier (2014)
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 8
-
G. Sonpavde, T. Choueiri (2012)
Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinomaBritish Journal of Cancer, 107
-
R. Motzer, N. Bander, D. Nanus (1996)
Renal-cell carcinoma.The New England journal of medicine, 335 12
-
C. Sternberg, I. Davis, J. Mardiak, C. Szczylik, Eunsik Lee, J. Wagstaff, C. Barrios, P. Salman, O. Gladkov, A. Kavina, J. Zarbá, Mei Chen, L. McCann, L. Pandite, D. Roychowdhury, R. Hawkins (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 41
-
C. Straka, D.W. Kim, Robert Timmerman, I. Pedrosa, C. Jacobs, J. Brugarolas (2013)
Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 23
-
D. Sandock, A. Seftel, Martin Resnick (1995)
A new protocol for the followup of renal cell carcinoma based on pathological stage.The Journal of urology, 154 1
-
R. Thompson, Haidong Dong, C. Lohse, B. Leibovich, M. Blute, J. Cheville, E. Kwon (2007)
PD-1 Is Expressed by Tumor-Infiltrating Immune Cells and Is Associated with Poor Outcome for Patients with Renal Cell CarcinomaClinical Cancer Research, 13
-
T. Choueiri, B. Escudier, T. Powles, P. Mainwaring, B. Rini, F. Donskov, H. Hammers, Thomas Hutson, Jae-Lyun Lee, K. Peltola, B. Roth, G. Bjarnason, L. Geczi, B. Keam, P. Maroto, D. Heng, M. Schmidinger, P. Kantoff, A. Borgman-Hagey, C. Hessel, C. Scheffold, G. Schwab, N. Tannir, R. Motzer (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.The New England journal of medicine, 373 19
-
T. Choueiri, D. Figueroa, P. Fay, S. Signoretti, Yuan Liu, R. Gagnon, K. Deen, C. Carpenter, Peter Benson, T. Ho, L. Pandite, P. Souza, T. Powles, R. Motzer (2014)
Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled TrialClinical Cancer Research, 21
-
Caleb Davis, C. Ricketts, Min Wang, Lixing Yang, A. Cherniack, Hui Shen, C. Buhay, Hyojin Kang, Sang Kim, Catherine Fahey, K. Hacker, G. Bhanot, D. Gordenin, Andy Chu, P. Gunaratne, Michael Biehl, S. Seth, Benny Kaipparettu, C. Bristow, L. Donehower, E. Wallen, Angela Smith, S. Tickoo, P. Tamboli, V. Reuter, L. Schmidt, J. Hsieh, T. Choueiri, A. Hakimi, L. Chin, M. Meyerson, R. Kucherlapati, W. Park, A. Robertson, P. Laird, E. Henske, D. Kwiatkowski, P. Park, M. Morgan, B. Shuch, D. Muzny, D. Wheeler, W. Linehan, R. Gibbs, W. Rathmell, C. Creighton (2014)
The somatic genomic landscape of chromophobe renal cell carcinoma.Cancer cell, 26 3
-
A. Ravaud, S. Oudard, M. Fromont, C. Chevreau, G. Gravis, S. Zanetta, C. Théodore, M. Jimenez, E. Sevin, B. Laguerre, F. Rolland, M. Ouali, S. Culine, B. Escudier (2015)
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.Annals of oncology : official journal of the European Society for Medical Oncology, 26 6
-
B. Escudier, A. Płużańska, P. Koralewski, A. Ravaud, S. Bracarda, C. Szczylik, C. Chevreau, Marek Filipek, B. Melichar, E. Bajetta, V. Gorbunova, J. Bay, I. Bodrogi, A. Jagiełło-Gruszfeld, N. Moore (2007)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 370
-
M. Michaelson, R. McKay, L. Werner, M. Atkins, E. Allen, Kara Olivier, Jiaxi Song, S. Signoretti, D. McDermott, T. Choueiri (2015)
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinomaCancer, 121
-
J. Srigley, B. Delahunt, J. Eble, L. Egevad, J. Epstein, D. Grignon, O. Hes, H. Moch, R. Montironi, S. Tickoo, Ming Zhou, P. Argani (2013)
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal NeoplasiaThe American Journal of Surgical Pathology, 37
-
D. Heng, J. Wells, B. Rini, B. Beuselinck, Jae-Lyun Lee, J. Knox, G. Bjarnason, S. Pal, C. Kollmannsberger, T. Yuasa, S. Srinivas, F. Donskov, A. Bamias, L. Wood, D. Ernst, N. Agarwal, U. Vaishampayan, S. Rha, Jenny Kim, T. Choueiri (2014)
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.European urology, 66 4
-
R. Motzer, B. Escudier, S. Oudard, Thomas Hutson, C. Porta, S. Bracarda, V. Grünwald, John Thompson, R. Figlin, N. Hollaender, A. Kay, A. Ravaud (2010)
Phase 3 trial of everolimus for metastatic renal cell carcinomaCancer, 116
-
S. Dabestani, A. Thorstenson, P. Lindblad, U. Harmenberg, B. Ljungberg, S. Lundstam (2016)
Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based studyWorld Journal of Urology, 34
-
R. Motzer, B. Escudier, S. Oudard, Thomas Hutson, F. Group (2008)
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 372
-
T. Choueiri, U. Vaishampayan, Jonathan Rosenberg, Theodore Logan, A. Harzstark, Ronald Bukowski, B. Rini, S. Srinivas, Mark Stein, Laurel Adams, L. Ottesen, Kevin Laubscher, L. Sherman, D. McDermott, Naomi Haas, Keith Flaherty, R. Ross, P. Eisenberg, Paul Meltzer, Maria Merino, D. Bottaro, W. Linehan, R. Srinivasan (2013)
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 2
-
J. Klapper, Stephanie Downey, F. Smith, J. Yang, M. Hughes, U. Kammula, R. Sherry, R. Royal, S. Steinberg, S. Rosenberg (2008)
High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinomaCancer, 113
-
R. Motzer, Thomas Hutson, H. Glen, M. Michaelson, A. Molina, T. Eisen, J. Jassem, J. Zolnierek, J. Maroto, B. Mellado, B. Melichar, J. Tomasek, A. Kremer, H. Kim, K. Wood, C. Dutcus, J. Larkin (2015)
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.The Lancet. Oncology, 16 15
-
C. Sternberg, R. Hawkins, J. Wagstaff, P. Salman, J. Mardiak, C. Barrios, J. Zarbá, O. Gladkov, Eunsik Lee, C. Szczylik, L. McCann, S. Rubin, Mei Chen, I. Davis (2013)
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.European journal of cancer, 49 6
-
D. Nanus, Alexandria Garino, M. Milowsky, M. Larkin, J. Dutcher (2004)
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinomaCancer, 101
-
S. Négrier, G. Gravis, D. Pérol, C. Chevreau, R. Delva, J. Bay, E. Blanc, C. Ferlay, L. Geoffrois, F. Rolland, E. Legouffe, E. Sevin, B. Laguerre, B. Escudier (2011)
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.The Lancet. Oncology, 12 7
-
Chad Ro, Chad Gibbs, C. Creighton, M. Morgan, P. Gunaratne, D. Wheeler, R. Gibbs, A. Chu, A. Robertson, Andy Chu, Rameen Cibulskis, R. Beroukhim, K. Cibulskis, S. Signoretti, Fabio Raphael, Fabio Wu, Benjamin Raphael, Roel Weinstein, R. Verhaak, P. Tamboli, Wandaliz Torres-García, R. Akbani, J. Weinstein, Victor Ciri, V. Reuter, J. Hsieh, A. Brannon, A. Hakimi, A. Jacobsen, G. Ciriello, B. Reva, Christopher Linehan, C. Ricketts, W. Linehan, Joshua Stuart, W. Rathmell, Hui Laird, Hui Shen, P. Laird, Donna Benton, D. Muzny, Caleb Davis, Liu Xi, K. Chang, N. Kakkar, L. Treviño, Susan Benton, J. Reid, Donna Morton, H. Doddapaneni, Yi Han, L. Lewis, H. Dinh, C. Kovar, Yiming Zhu, J. Santibanez, Min Wang, Walker Hale, D. Kalra, Gad Sivachenko, G. Getz, Mike Lawrence, C. Sougnez, S. Carter, A. Sivachenko, Lee Lichtenstein, C. Stewart, Douglas Voet, Sheila Fisher, Stacey Gabriel, E. Lander, Rameen Carter, Steve Schumacher, B. Tabak, Gordon Saksena, R. Onofrio, A. Cherniack, Jeff Gentry, K. Ardlie, Carrie Sougnez, S. Gabriel, M. Meyerson, A. Sto, Hye-Jung Chun, A. Mungall, Payal Sipahimalani, D. Stoll, Adrian Ally, M. Balasundaram, Y. Butterfield, R. Carlsen, Candace Carter, E. Chuah, R. Coope, Noreen Dhalla, S. Gorski, R. Guin, Carrie Hirst, M. Hirst, R. Holt, Chandra Lebovitz, Darlene Lee, H. Li, Michael Mayo, Richard Moore, E. Pleasance, Patrick Plettner, J. Schein, A. Shafiei, Jared Slobodan, Angela Tam, N. Thiessen, R. Varhol, N. Wye, Yongjun Zhao, I. Birol, Steven Jones, M. Marra, J.Todd Jefferys, J. Auman, Donghui Tan, Corbin Jones, K. Hoadley, P. Mieczkowski, Lisle Mose, S. Jefferys, M. Topal, C. Liquori, Yidi Turman, Yan Shi, S. Waring, Elizabeth Buda, J. Walsh, Junyuan Wu, T. Bodenheimer, A. Hoyle, J. Simons, Mathew Soloway, S. Balu, J. Parker, D. Hayes, C. Perou, Raju Park, R. Kucherlapati, Peter Park, Hui Maglinte, Timothy Jr, D. Weisenberger, Phillip Lai, M. Bootwalla, D. Maglinte, S. Mahurkar, B. Berman, D. Berg, L. Cope, S. Baylin, C. Wheeler, Gad Voet, M. Noble, D. Dicara, Hailei Zhang, Juok Cho, David Heiman, N. Gehlenborg, William Mallard, Pei Lin, S. Frazer, P. Stojanov, Yingchun Liu, Lihua Zhou, Jaegil Kim, L. Chin, Fabio Raphael, Fabio Vandin, Hsin-Ta Wu, Christopher Yau, Christopher Benz, C. Yau, Sheila Shmulevich, Sheila Reynolds, I. Shmulevich, Roel Jo, R. Verhaak, Rahulsimham Vegesna, Hoon Kim, Wei Zhang, D. Cogdell, E. Jonasch, Z. Ding, Yiling Lu, Nianxiang Zhang, A. Unruh, Tod Casasent, Chris Wakefield, D. Tsavachidou, G. Mills, Anders Hakimi, N. Schultz, Yevgeniy Antipin, Jianjiong Gao, E. Cerami, Benjamin Gross, B. Aksoy, Rileen Sinha, Nils Weinhold, S. Sumer, B. Taylor, R. Shen, I. Ostrovnaya, M. Berger, M. Ladanyi, C. Sander, Suzanne Spellman, S. Fei, Andrew Stout, P. Spellman, Daniel Liu, D. Rubin, T. Liu, Joshua Z, S. Ng, Evan Paull, Daniel Carlin, Theodore Goldstein, Peter Waltman, K. Ellrott, Jing-Ping Zhu, D. Haussler, Preethi Xiao, W. Xiao, Candace Paula, C. Shelton, J. Gardner, R. Penny, M. Sherman, D. Mallery, S. Morris, J. Paulauskis, K. Burnett, T. Shelton, William Choueiri, W. Kaelin, T. Choueiri, M. Atkins, Robert Curley, Erin Curley, Satish Reuter, S. Tickoo, W. Fisher, L. Thorne, L. Boice, Mei Huang, J. Fisher, W. Schm, C. Vocke, James Peterson, R. Worrell, Maria Merino, Laura Schmidt, Pheroze Wood, B. Czerniak, K. Aldape, C. Wood, Jeff Weaver, J. Boyd, J. Weaver, Mary Huelsenbe, M. Iacocca, N. Petrelli, G. Witkin, Jennifer Brown, Christine Czerwinski, L. Huelsenbeck-Dill, B. Rabeno, Jerome A, J. Myers, Carl Morrison, Julie Bergsten, J. Eckman, Jodi Harr, Christine Smith, Kelinda Tucker, Leigh Zach, Wiam Morrison, W. Bshara, Carmelo Gaudioso, Carl Morrison, Rajiv Parwani, R. Dhir, J. Maranchie, J. Nelson, A. Parwani, O. Potapova, K. Fedosenko, John Thompson, J. Cheville, R. Thompson, W. Schmidt, Juan Rubin, J. Mosquera, M. Rubin, M. Blute, Todd Pontius, T. Pihl, M. Jensen, R. Sfeir, A. Kahn, A. Chu, Prachi Kothiyal, Eric Snyder, J. Pontius, Brenda Ayala, M. Backus, Jessica Walton, J. Baboud, D. Berton, M. Nicholls, Deepak Srinivasan, R. Raman, Stanley Girshik, Peter Kigonya, S. Alonso, Rashmi Sanbhadti, S. Barletta, D. Pot, Margi E, Margi Sheth, John Demchok, Tanja Davidsen, Zhining Wang, Liming Yang, R. Tarnuzzer, J. Zhang, G. Eley, M. Ferguson, Kenna Shaw, Mark Sofia., M. Guyer, B. Ozenberger, H. Sofia (2013)
Comprehensive molecular characterization of clear cell renal cell carcinomaNature, 499
-
I. Varela, P. Tarpey, K. Raine, Dachuan Huang, C. Ong, P. Stephens, H. Davies, David Jones, Meng‐Lay Lin, J. Teague, G. Bignell, A. Butler, Juok Cho, G. Dalgliesh, Danushka Galappaththige, C. Greenman, Claire Hardy, Mingming Jia, Calli Latimer, K. Lau, J. Marshall, Stuart Mclaren, A. Menzies, L. Mudie, L. Stebbings, D. Largaespada, L. Wessels, S. Richard, R. Kahnoski, J. Anema, D. Tuveson, P. Pérez-Mancera, Ville Mustonen, Andrej Fischer, David Adams, A. Rust, W. Chan-on, Chutima Subimerb, Karl Dykema, K. Furge, Peter Campbell, Bin Teh, Michael Stratton, P. Futreal (2010)
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinomaNature, 469
-
B. Escudier, J. Bellmunt, S. Négrier, E. Bajetta, B. Melichar, S. Bracarda, A. Ravaud, S. Golding, S. Jethwa, V. Sneller (2010)
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 13
-
R. Rabinovitch, M. Zelefsky, J. Gaynor, Z. Fuks (1994)
Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 1
-
G. Mickisch, A. Garin, H. Poppel, L. Prijck, R. Sylvester (2001)
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialThe Lancet, 358
-
D. Heng, W. Xie, M. Regan, M. Warren, A. Golshayan, C. Sahi, B. Eigl, J. Ruether, T. Cheng, S. North, P. Venner, J. Knox, K. Chi, C. Kollmannsberger, D. McDermott, W. Oh, M. Atkins, R. Bukowski, B. Rini, T. Choueiri (2009)
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 34
-
B. Rini, S. Halabi, J. Rosenberg, W. Stadler, D. Vaena, S. Ou, L. Archer, J. Atkins, J. Picus, P. Czaykowski, J. Dutcher, E. Small (2008)
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 33
-
R. Siegel, K. Miller, A. Jemal (2016)
Cancer statistics, 2016CA: A Cancer Journal for Clinicians, 66
-
R. Motzer, B. Rini, D. McDermott, B. Redman, T. Kuzel, M. Harrison, U. Vaishampayan, H. Drabkin, S. George, T. Logan, K. Margolin, E. Plimack, A. Lambert, I. Waxman, H. Hammers (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 13
-
M. Voss, A. Hakimi, C. Pham, A. Brannon, Ying-bei Chen, Luis Cunha, O. Akin, Han Liu, Shugaku Takeda, Sasinya Scott, N. Socci, A. Viale, N. Schultz, C. Sander, V. Reuter, P. Russo, E. Cheng, R. Motzer, M. Berger, J. Hsieh (2014)
Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor TherapyClinical Cancer Research, 20
-
W. Kaelin (2008)
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancerNature Reviews Cancer, 8
-
B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Négrier, C. Chevreau, E. Solska, A. Desai, F. Rolland, T. Demkow, Thomas Hutson, M. Gore, S. Freeman, B. Schwartz, M. Shan, R. Simantov, R. Bukowski (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma.The New England journal of medicine, 356 2
-
M. Gerlinger, A. Rowan, S. Horswell, M. Math, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, Sharmin Begum, N. McDonald, A. Butler, David Jones, K. Raine, Calli Latimer, Claudio Santos, M. Nohadani, A. Eklund, B. Spencer‐Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P. Futreal, C. Swanton (2012)
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.The New England journal of medicine, 366 10
-
S. Oudard, E. Banu, A. Vieillefond, L. Fournier, F. Priou, J. Medioni, A. Banu, B. Duclos, F. Rolland, B. Escudier, Nina Arakelyan, S. Culine (2007)
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.The Journal of urology, 177 5
-
B. Rini, M. Atkins (2009)
Resistance to targeted therapy in renal-cell carcinoma.The Lancet. Oncology, 10 10
-
R. Motzer, B. Escudier, D. McDermott, S. George, H. Hammers, S. Srinivas, S. Tykodi, J. Sosman, G. Procopio, E. Plimack, D. Castellano, T. Choueiri, H. Gurney, F. Donskov, P. Bono, J. Wagstaff, T. Gauler, Takeshi Ueda, Yoshihiko Tomita, F. Schutz, C. Kollmannsberger, J. Larkin, A. Ravaud, J. Simon, Li-an Xu, I. Waxman, P. Sharma (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.The New England journal of medicine, 373 19
-
F. Vera-Badillo, A. Templeton, I. Durán, A. Ocaña, P. Gouveia, P. Aneja, J. Knox, I. Tannock, B. Escudier, E. Amir (2015)
Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis.European urology, 67 4
-
D. Cella, V. Grünwald, P. Nathan, J. Doan, H. Dastani, F. Taylor, B. Bennett, M. Derosa, S. Berry, K. Broglio, E. Berghorn, R. Motzer (2016)
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.The Lancet. Oncology, 17 7
-
A. Sankin, A. Hakimi, J. Hsieh, A. Molina (2015)
Metastatic Non-Clear Cell Renal Cell Carcinoma: An Evidence Based Review of Current Treatment StrategiesFrontiers in Oncology, 5
-
N. Hanna, M. Sun, C. Meyer, P. Nguyen, S. Pal, Steven Chang, G. Velasco, Q. Trinh, T. Choueiri (2016)
Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 27
-
R. Motzer, Thomas Hutson, P. Tomczak, M. Michaelson, R. Bukowski, O. Rixe, S. Oudard, S. Négrier, C. Szczylik, Sindy Kim, I. Chen, P. Bycott, C. Baum, R. Figlin (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.The New England journal of medicine, 356 2
-
R. McKay, N. Kroeger, W. Xie, Jae-Lyun Lee, J. Knox, G. Bjarnason, M. Mackenzie, L. Wood, S. Srinivas, U. Vaishampayan, S. Rha, S. Pal, F. Donskov, S. Tantravahi, B. Rini, D. Heng, T. Choueiri (2014)
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.European urology, 65 3
-
T. Shaikh, E. Handorf, C. Murphy, A. Kutikov, R. Uzzo, M. Hallman, E. Horwitz, M. Smaldone (2015)
Contemporary Trends in the Utilization of Radiotherapy in Patients With Renal Cell Carcinoma.Urology, 86 6
-
J. Calderaro, J. Moroch, G. Pierron, F. Pedeutour, Camille Grison, P. Maillé, P. Soyeux, A. taille, J. Couturier, A. Vieillefond, M. Rousselet, O. Delattre, Y. Allory (2012)
SMARCB1/INI1 inactivation in renal medullary carcinomaHistopathology, 61
-
R. Motzer, J. Bacik, B. Murphy, P. Russo, M. Mazumdar (2002)
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 1
-
Lijun Zhou, Xian-de Liu, Mianen Sun, Xuesong Zhang, P. Germán, S. Bai, Z. Ding, N. Tannir, C. Wood, S. Matin, J. Karam, P. Tamboli, K. Sircar, P. Rao, E. Rankin, D. Laird, A. Hoang, C. Walker, A. Giaccia, E. Jonasch (2016)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinomaOncogene, 35
-
D. Sabatini (2006)
mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 6
-
L. Valença, M. Hirsch, T. Choueiri, L. Harshman (2015)
Non-clear cell renal cell carcinoma, part 2: therapy.Clinical advances in hematology & oncology : H&O, 13 6
-
D. Kwiatkowski, B. Manning (2014)
Molecular basis of giant cells in tuberous sclerosis complex.The New England journal of medicine, 371 8
-
G. Iyer, Aphrothiti Hanrahan, M. Milowsky, H. Al-Ahmadie, Sasinya Scott, M. Janakiraman, Mono Pirun, C. Sander, N. Socci, I. Ostrovnaya, A. Viale, A. Heguy, L. Peng, T. Chan, B. Bochner, D. Bajorin, M. Berger, B. Taylor, D. Solit (2012)
Genome Sequencing Identifies a Basis for Everolimus SensitivityScience, 338
-
A. Armstrong, S. Halabi, T. Eisen, S. Broderick, W. Stadler, Robert Jones, Jorge Garcia, U. Vaishampayan, J. Picus, R. Hawkins, J. Hainsworth, C. Kollmannsberger, T. Logan, I. Puzanov, L. Pickering, C. Ryan, A. Protheroe, C. Lusk, Sadie Oberg, D. George (2016)
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.The Lancet. Oncology, 17 3
-
T. Choueiri, B. Escudier, T. Powles, N. Tannir, P. Mainwaring, B. Rini, H. Hammers, F. Donskov, B. Roth, K. Peltola, J. Lee, D. Heng, M. Schmidinger, N. Agarwal, C. Sternberg, D. McDermott, D. Aftab, C. Hessel, C. Scheffold, G. Schwab, Thomas Hutson, S. Pal, R. Motzer (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.The Lancet. Oncology, 17 7
-
A. Hakimi, I. Ostrovnaya, B. Reva, N. Schultz, Ying-bei Chen, M. Gonen, Han Liu, Shugaku Takeda, M. Voss, S. Tickoo, V. Reuter, P. Russo, E. Cheng, C. Sander, R. Motzer, J. Hsieh (2013)
Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research NetworkClinical Cancer Research, 19
-
Jianmin Wang, A. Papanicolau‐Sengos, Sreenivasulu Chintala, Lei Wei, Biao Liu, Q. Hu, K. Miles, J. Conroy, S. Glenn, M. Costantini, C. Magi-Galluzzi, S. Signoretti, T. Choueiri, M. Gallucci, S. Sentinelli, V. Fazio, M. Poeta, Song Liu, C. Morrison, R. Pili (2016)
Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulationOncotarget, 7
-
A. Ravaud, C. Barrios, B. Alekseev, M. Tay, S. Agarwala, Ş. Yalçın, C. Lin, L. Roman, M. Shkolnik, Ö. Anak, S. Gogov, D. Pelov, A. Louveau, B. Melichar (2015)
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma.Annals of oncology : official journal of the European Society for Medical Oncology, 26 7
-
D. McDermott, Su-Chun Cheng, S. Signoretti, K. Margolin, Joseph Clark, J. Sosman, J. Dutcher, T. Logan, B. Curti, M. Ernstoff, L. Appleman, M. Wong, N. Khushalani, L. Oleksowicz, U. Vaishampayan, J. Mier, D. Panka, R. Bhatt, A. Bailey, B. Leibovich, E. Kwon, F. Kabbinavar, A. Belldegrun, R. Figlin, A. Pantuck, M. Regan, M. Atkins (2014)
The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell CarcinomaClinical Cancer Research, 21
-
R. Motzer, T. Hutson, L. McCann, K. Deen, T. Choueiri (2014)
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.The New England journal of medicine, 370 18
-
N. Haas, Xinyi Lin, J. Manola, M. Pins, Glenn Liu, D. McDermott, D. Nanus, E. Heath, G. Wilding, J. Dutcher (2012)
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802Medical Oncology, 29
-
B. Rini, S. Halabi, J. Rosenberg, W. Stadler, D. Vaena, L. Archer, J. Atkins, J. Picus, P. Czaykowski, J. Dutcher, E. Small (2010)
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 13
-
S. Peña-Llopis, S. Vega-Rubín-de-Celis, S. Vega-Rubín-de-Celis, A. Liao, Nan Leng, Andrea Pavía-Jiménez, Andrea Pavía-Jiménez, Shanshan Wang, Shanshan Wang, Toshinari Yamasaki, Toshinari Yamasaki, Leah Zhrebker, Leah Zhrebker, S. Sivanand, S. Sivanand, Patrick Spence, Patrick Spence, L. Kinch, T. Hambuch, Suneer Jain, Y. Lotan, V. Margulis, A. Sagalowsky, P. Summerour, Wareef Kabbani, S. Wong, N. Grishin, M. Laurent, Xian-Jin Xie, C. Haudenschild, M. Ross, D. Bentley, Payal Kapur, J. Brugarolas (2012)
BAP1 loss defines a new class of renal cell carcinomaNature genetics, 44
-
D. Heng, T. Choueiri (2009)
Non-clear cell renal cancer: features and medical management.Journal of the National Comprehensive Cancer Network : JNCCN, 7 6
-
F. Latif, K. Tory, J. Gnarra, M. Yao, F. Duh, M. Orcutt, T. Stackhouse, I. Kuzmin, W. Modi, L. Geil (1993)
Identification of the von Hippel-Lindau disease tumor suppressor gene.Science, 260 5112
-
R. Flanigan, S. Salmon, B. Blumenstein, S. Bearman, V. Roy, P. Mcgrath, J. Caton, Nikhil Munshi, E. Crawford (2001)
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.The New England journal of medicine, 345 23
-
L. Harshman, C. Drake, T. Choueiri (2014)
PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and BeyondCancer Immunology Research, 2
-
R. Motzer, Thomas Hutson, P. Tomczak, M. Michaelson, R. Bukowski, S. Oudard, S. Négrier, C. Szczylik, R. Pili, G. Bjarnason, X. Garcia-Del-Muro, J. Sosman, E. Solska, G. Wilding, John Thompson, Sindy Kim, I. Chen, Xin Huang, R. Figlin (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 41
- Publisher
- The New England Journal of Medicine
- Copyright
- Copyright © 2017 Massachusetts Medical Society. All rights reserved.
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- DOI
- 10.1056/NEJMra1601333
- pmid
- 28121507
- Publisher site
- See Article on Publisher Site
Abstract
Kidney cancers have been extensively studied, and insights from an increased understanding of tumor biology have led to increases in survival rates. Therapies aimed at tumor signaling pathways and immunotherapies have improved the outlook for patients with renal cancer.
Journal
The New England Journal of Medicine – The New England Journal of Medicine
Published: Jan 26, 2017